Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 2 6Phase 1/2 4Phase 1 1

Status

Recruiting 3Active not recruiting 3

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 4Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 3Sarcoma 1Liposarcoma 1Leiomyosarcoma 1HER2 Negative Breast Cancer 1Endometrial Neoplasms 1

Interventions

Specimen Handling 176Magnetic Resonance Spectroscopy 138Biopsy 102pembrolizumab 81Carboplatin 79Cisplatin 71Nivolumab 65Cyclophosphamide 64Paclitaxel 54Radiotherapy 48Gemcitabine 43durvalumab 39Doxorubicin 35Bevacizumab 34Fluorouracil 33venetoclax 32Dexamethasone 31Rituximab 30atezolizumab 29Radiation 29Capecitabine 28Lenalidomide 27Etoposide 27Prednisone 26Oxaliplatin 26Injections 26Pemetrexed 25Docetaxel 25olaparib 23fludarabine 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × ribociclib × 30 days × Clear all
NCT06953882 2026-05-26

SELECT

Yale University

Phase 2 Recruiting
140 enrolled
Breast

HER2 Negative Breast Cancer

NCT07054190 2026-05-26

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Hoffmann-La Roche

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms

NCT03008408 2026-05-22

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
90 enrolled
Gynecologic

Endometrial Neoplasms

NCT03114527 2026-05-22

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Fox Chase Cancer Center

Phase 2 Active not recruiting
48 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT07405801 2026-05-18

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Hoffmann-La Roche

Phase 2 Recruiting
80 enrolled
Breast

Breast Neoplasms

NCT05296746 2026-05-14

RIBOLARIS

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
1,100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡